Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Verici Dx Plc (VRCI)

London
Currency in GBP
Disclaimer
8.35
+0.35(+4.38%)
Real-time Data
VRCI Scorecard
Fair Value
Unlock Value
Day's Range
7.758.35
52 wk Range
5.5019.00
Bid/Ask
7.50 / 8.50
Prev. Close
8
Open
7.75
Day's Range
7.75-8.35
52 wk Range
5.5-19
Volume
85,868
Average Vol. (3m)
333,841
1-Year Change
-34.43%
Shares Outstanding
242,541,467
Fair Value
Unlock
Dividends Payment Streak
Unlock
Analysts
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell

People Also Watch

0.14
DGI
-3.51%
1.598
HEMO
-0.06%
6.16
EAAS
-0.65%
52.90
SFOR
-5.03%
How do you feel today about VRCI?
Vote to see community's results!
or

Verici Dx Plc Company Profile

Verici Dx plc, an immuno-diagnostics development company, focuses on the kidney transplantation market. The company develops prognostic and diagnostic tests for kidney transplant patients. Its lead products comprise Tutivia, a post-transplant test focused on acute rejection, including sub-clinical rejection; and Clarava, a pre-transplant prognosis test for the risk of early acute rejection. The company also develops Protega, a peripheral blood-based test that aims to predict the risk of fibrosis and long-term graft failure. Verici Dx plc was incorporated in 2020 and is based in Penarth, the United Kingdom.

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.